Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 6/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9059857 | 0.83 | OPRK1 (0.47) | LMNAPOLBMAPTOPRK1PDE3A | |
| SCHEMBL21272260 | 0.82 | LMNA (0.53) | LMNAPOLBMAPTOPRK1PDE3A | |
| SCHEMBL21272257 | 0.82 | LMNA (0.53) | LMNAPOLBMAPTOPRK1PDE3A | |
| SCHEMBL29544459 | 0.80 | OPRK1 (0.54) | LMNAOPRK1PDE3AHTR2BPDE4D | |
| SCHEMBL29410184 | 0.80 | OPRK1 (0.54) | LMNAOPRK1PDE3AHTR2BPDE4D | |
| SCHEMBL1687457 | 0.80 | OPRK1 (0.54) | LMNAOPRK1PDE3AHTR2BPDE4D | |
| SCHEMBL9061591 | 0.79 | OPRK1 (0.44) | LMNAPOLBMAPTOPRK1PDE3A | |
| SCHEMBL6124975 | 0.79 | HDAC3 (0.50) | LMNAOPRK1PDE3A | |
| SCHEMBL13948824 | 0.79 | OPRK1 (0.51) | LMNAPOLBMAPTOPRK1PDE3A | |
| SCHEMBL5619577 | 0.78 | HDAC3 (0.54) | LMNAOPRK1PDE3ATP53HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077805-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2422788-A2 | Benzodiazepines and compositions and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7994313-B2 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080293700-A1 | Compositions and Methods Relating to Novel Compounds and Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2008-11-27 | — | — | US | disclosed |
| US-20080293700-A1 | Compositions and Methods Relating to Novel Compounds and Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2008-11-27 | — | — | US | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293700-A1 | Compositions and Methods Relating to Novel Compounds and Targets Thereof | BAX, BAD, GABRB3 | LMNA 2518/4885POLB 2647/4885MAPT 1416/4885 |
| US-20120077805-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | GABRA5, GABRA3, GABRA6 | LMNA 1390/4885POLB 3400/4885MAPT 365/4885 |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | GABRA5, GABRA3, GABRA6 | LMNA 1390/4885POLB 3400/4885MAPT 365/4885 |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | GABRA5, GABRA3, GABRA6 | LMNA 1390/4885POLB 3400/4885MAPT 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.